ElizabethAGriffithsMD

PubMed

• The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
  Cecilia A Castellano, Tianyi Sun, Deepak Ravindranathan, Clara Hwang, Nino Balanchivadze, Sunny R K Singh, Elizabeth A Griffiths, Igor Puzanov, Erika Ruiz-Garcia, Dian...> ;Cancer. 2024 Feb 20
• Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
  Gail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, Karen Yee, Hagop Kantarjian, Christian Récher, Michael T Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine...> ;Blood Advances. 2024 Apr 23
• 3 citations
  Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...
  Garcia-Manero, G., McCloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H., Patel, P., Sabloff, M., Keating, M., Zhu, N., Gabrail, N., Fazal, S., Maly...> ;The Lancet. Haematology. 2024 Jan 1
• 1 citations
  Transfusion avoidance in myelodysplastic neoplasms.
  Elizabeth A Griffiths> ;Current Opinion in Hematology. 2024 Mar 1
• ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.
  Hassan Awada, Manasa Bhatta, Han Yu, Wenyan Ji, Surui Hou, Tara Cronin, Sheeba Ba Aqeel, Arya Mariam Roy, Muhammad Salman Faisal, Peter Kouides, John Mascarenhas, Eliz...> ;Leukemia. 2024 Jan 1
• 6 citations
  Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
  Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
• 1 citations
  Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
  Vikas, P., Shuchi Gulati, Chih-Yuan Hsu, Surbhi Shah, Pankil K Shah, Rebecca Zon, Susan Alsamarai, Joy Awosika, Ziad El-Bakouny, Babar Bashir, Alicia Beeghly, Stephani...> ;JAMA Oncology. 2023 Oct 1
• 1 citations
  Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
  Hassan Awada, Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark Faber, Matthew Gravina, Pamela J Sung, Steven D ...> ;Blood Cancer Journal. 2023 Sep 4
• 1 citations
  Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
  Pierre Fenaux, Marco Gobbi, Patricia L Kropf, Jean-Pierre J Issa, Gail J Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw W Jedrz...> ;Blood Advances. 2023 Sep 12
• Evaluation of hypereosinophilia in a case of-mutant acute myeloid leukemia treated with gilteritinib.
  Leslie N Martinez-Gutierrez, Blake C Burgher, Manuel J Glynias, Daniel Alvarado, Elizabeth A Griffiths, Sean T Glenn, Pamela J Sung> ;Cold Spring Harbor Molecular Case Studies. 2023 Jun 1
• FLT3-mutated acute myeloid leukaemia: a new opportunity.
  Amanda C Przespolewski, Elizabeth A Griffiths> ;Lancet. 2023 May 13
• 7 citations
  Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1International Workshop on MDS (iwMDS) Of t...
  Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M Brunner, Rena Buckstein, Hetty E Carraway, Jane E Churpek, Naval G Daver, ...> ;Blood Reviews. 2023 Jul 1
• 22 citations
  Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COV...
  Choueiri, T., Labaki, C., Bakouny, Z., Hsu, C., Schmidt, A., de Lima Lopes, G., Hwang, C., Singh, S., Jani, C., Weissmann, L., Griffiths, E., Halabi, S., Wu, U., Berg,...> ;Lancet Regional Health. Americas. 2023 Mar 1
• 29 citations
  Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
  Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Adès, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E Carraway, Naval...> ;Blood. 2023 Apr 27
• MEETING HIGHLIGHTS: THE THIRD MARIE SKŁODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2...
  Kalinski, P., Kokolus, K., Azrak, R., Berezin, M., Brentjens, R., Czerniecki, B., Dubrov, S., Eaton, K., Hyland, A., Kisailus, A., Kortylewski, M., Koski, G., Kotula, ...> ;Wiadomosci Lekarskie. 2023 Jan 1
• Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
  Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famu...> ;Blood. 2023 Mar 23
• 13 citations
  Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
  Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A Sekeres, David P Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M ...> ;Leukemia. 2022 Dec 1
• 4 citations
  An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.
  Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F Sanz, David A Sallman, Vale...> ;Blood Advances. 2023 Jun 27
• 3 citations
  Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
  Wagner, M., Hennessy, C., Beeghly, A., French, B., Shah, D., Croessmann, S., Vilar-Compte, D., Ruiz-Garcia, E., Ingham, M., Schwartz, G., Painter, C., Chugh, R., Feche...> ;Cancers. 2022 Sep 5
• 7 citations
  Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.
  Jurjen Versluis, Manu Pandey, Yael Flamand, J Erika Haydu, Roger Belizaire, Mark Faber, Rahul S Vedula, Anne Charles, Kevin M Copson, Shai Shimony, Alon Rozental, Pava...> ;Blood Advances. 2022 May 10
• 10 citations
  Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia.
  Lorenza Bellusci, Gabrielle Grubbs, Pragya Srivastava, Michael J Nemeth, Elizabeth A Griffiths, Hana Golding, Surender Khurana> ;Blood. 2022 May 5
• 13 citations
  Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
  Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novák, Wieslaw W Jedrzejczak, Xavier Thomas...> ;Blood. 2022 Jul 21
• 21 citations
  NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
  Elizabeth A Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Rita Cool, Shira Dinner, Mark Geyer, John Glaspy, Ivana Gojo, Ashley Hicks, Avyakta Kalla...> ;Journal of the National Comprehensive Cancer Network. 2022 May 1
• 5 citations
  Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
  Satyanarayana, G., Enriquez, K., Sun, T., Klein, E., Abidi, M., Advani, S., Awosika, J., Bakouny, Z., Bashir, B., Berg, S., Bernardes, M., Egan, P., Elkrief, A., Feldm...> ;Open Forum Infectious Diseases. 2022 Mar 1
• 45 citations
  NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
  Peter L Greenberg, Richard M Stone, Aref Al-Kali, John M Bennett, Uma Borate, Andrew M Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M de Castro, H Joachim Deeg, Amy ...> ;Journal of the National Comprehensive Cancer Network. 2022 Feb 1
• Join now to see all

Abstracts/Posters

• Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Tran...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients wit...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A ...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inhibition of LSD1 in Myelodysplastic Syndrome Progenitors Restores Differentiation of CD141Hi Conventional Dendritic Cells
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Quantification of Humoral Immune Response to Influenza Vaccination in MDS
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
  Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Acute Myeloid Leukemia: Moving Beyond 7+3 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Acute Myeloid Leukemia: Moving Beyond 7+4 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018